Dainippon Sumitomo Pharma Announces Results of Clinical Trial of Mosapride Citrate.Tokyo, Japan, Apr 27, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Dainippon Sumitomo Pharma announced on April 25 that it has presented the results of the Japan Mosapride Mega-Study (JMMS JMMS John Muir Middle School (California) JMMS Joan MacQueen Middle School (Alpine, CA) JMMS José Martí Middle School (Hialeah, FL) ), a large-scale randomized clinical trial randomized clinical trial, n a clinical study where volunteer participants with comparable characteristics are randomly assigned to different test groups to compare the efficacy of therapies. of mosapride citrate for functional dyspepsia (FD). The JMMS, which was led by the Japan-International Society for Gastrointestinal Motility motility /mo·til·i·ty/ (mo-til´ite) the ability to move spontaneously.mo´tile Motility Motility is spontaneous movement. , covered more than 1,000 patients in Japan. According to the announcement, the results of endoscopy showed that 91.2% of the subjects suspected of having FD don't have lesions. Therefore, the study concluded that FD is not necessarily related to histological lesions. Further, compared with the control drug, the administration of mosapride citrate can substantially improve gastrointestinal symptoms like stomachache stom·ach·ache n. Pain in the stomach or abdomen. stomachache Vox populi Gastralgia and heavy stomach feeling. Currently, Dainippon Sumitomo Pharma is marketing mosapride citrate under the trade name of Gasmotin. Details of the results were presented at the 92nd Annual Meeting of the Japanese Society of Gastroenterology held from April 20 to 22. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion